Gameto, a NYC- and Madrid, Spain-based biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system, raised an additional $17m in funding.
Backers included Insight Partners, Future Ventures, Arcadia Investment Partners, Bold Capital Partners, Plum Alley, Myelin VC, TA Ventures, Gaingels, Korify Capital, and other existing investors.
The company, which brought the total capital raised since inception to $40m, intends to use the funds to expand operations and its business reach.
Led by Dr. Dina Radenkovic, CEO, Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Its underlying cell engineering platform was developed in stealth under a scientific research agreement with George Church’s lab at Harvard Medical School. In January, the company announced plans for three sequenced programs. The first program, Fertilo, is a biologic for IVF and egg freezing, aiming to make the process shorter, safer, and more effective. The following programs include Deovo, an organoid of the female reproductive system, and Ameno, a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause.
Fertilo has entered preclinical development in partnership with leading clinics in the US and in Spain, the largest ART [Assisted Reproductive Technology] market in Europe. Partner clinics include Extend Fertility, RMA, Pozitivf, Ovation Fertility, Clinica Tambre, and Hospital Ruber Internacional.